Hemab Therapeutics IPO Raises $346.7M, Shares on Nasdaq

Hemab Therapeutics Completes $346.7 Million Initial Public Offering

Hemab Therapeutics Holdings, Inc. (COAG) has successfully closed its initial public offering, raising approximately $346.7 million in gross proceeds. The biotechnology company offered 19,262,500 shares to the public at a price of $18.00 per share before underwriting fees and related expenses.

Offering Details and Market Context

The offering included the full exercise of the underwriters' over-allotment option, accounting for 2,512,500 additional shares. Hemab's common stock began trading on the Nasdaq Global Select Market on May 1, 2026. The offering was managed by Goldman Sachs & Co. LLC, Jefferies, and Evercore ISI as joint book-running managers, with Wedbush PacGrow acting as the lead manager.

Company Focus and Pipeline

Based in Cambridge, Massachusetts, and Copenhagen, Hemab Therapeutics focuses on developing treatments for bleeding and thrombotic diseases. The newly acquired capital will likely support the advancement of its clinical pipeline, which includes sutacimig for Glanzmann thrombasthenia and Factor VII deficiency, and HMB-002 for Von Willebrand Disease.

Summary and Outlook

This upsized IPO marks a significant financial milestone for Hemab Therapeutics, providing substantial funding for its research and development programs. Market participants will now closely watch the clinical progress of its key therapeutic candidates and the stock's performance following its public debut. The SEC had declared the registration statement effective on April 30, 2026.

FAQ

Q: How much did Hemab Therapeutics raise in its IPO?
A: Hemab Therapeutics raised approximately $346.7 million in gross proceeds from its IPO by selling 19,262,500 shares at $18.00 each.

Q: What is Hemab Therapeutics' stock ticker?
A: The company's common stock trades on the Nasdaq Global Select Market under the ticker symbol COAG.

Q: What does Hemab Therapeutics specialize in?
A: The company is a clinical-stage biotechnology firm focused on discovering and developing novel therapies for serious bleeding and thrombotic disorders.

Source: Investing.com